Article
Immunology
Gregory J. Wilson, Benigno Rodriguez, Shuying Sue Li, Mary Allen, Ian Frank, Erika Rudnicki, Meg Trahey, Spyros Kalams, Drew Hannaman, David K. Clarke, Rong Xu, Michael Egan, John Eldridge, Michael Pensiero, Theresa Latham, Guido Ferrari, David C. Montefiori, Georgia D. Tomaras, Stephen C. De Rosa, Jeffrey M. Jacobson, Maurine D. Miner, Marnie Elizaga
Summary: This study evaluated the safety and immunogenicity of a DNA vaccine prime followed by a viral vector boost for HIV subtypes B and C. The results showed that the vaccine regimen was safe and tolerable, and induced immune responses to specific HIV antigens.
Article
Immunology
Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, Monde Muyoyeta, Allan C. deCamp, Zonglin He, Nicole Grunenberg, Faatima Laher Omar, Kelly E. Seaton, Laura Polakowski, Amanda S. Woodward Davis, Lucas Maganga, Lindsey R. Baden, Kenneth Mayer, Spyros Kalams, Michael Keefer, Srilatha Edupuganti, Benigno Rodriguez, Ian Frank, Hyman Scott, Lynda Stranix-Chibanda, Sanjay Gurunathan, Marguerite Koutsoukos, Olivier Van der Meeren, Carlos A. DiazGranados, Carmen Paez, Erica Andersen-Nissen, James Kublin, Lawrence Corey, Guido Ferrari, Georgia Tomaras, M. Juliana McElrath
Summary: This study evaluated the safety and immunogenicity of ALVAC-HIV vaccine with MF59 or AS01(B) adjuvants. The vaccines were generally safe and well tolerated, and the AS01(B) adjuvanted groups showed better immune responses. This study is significant for the development of HIV vaccines.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Amandine Gagneux-Brunon, Emilie Guyot, Maelle Detoc, Elisabeth Botelho-Nevers, Tiphaine Raia-Barjat
Summary: This study explored the attitudes of midwives towards pregnant individuals' participation in vaccine clinical trials. The results showed that only a small proportion of midwives were willing to encourage pregnant individuals to participate, while midwives with good vaccine training were more likely to support their participation in clinical trials.
Article
Medicine, General & Internal
Bruna Oriol-Tordera, Anna Esteve-Codina, Maria Berdasco, Miriam Rosas-Umbert, Elena Goncalves, Clara Duran-Castells, Francesc Catala-Moll, Anuska Llano, Samandhy Cedeno, Maria C. Puertas, Martin Tolstrup, Ole S. Sogaard, Bonaventura Clotet, Javier Martinez-Picado, Tomas Hanke, Behazine Combadiere, Roger Paredes, Dennis Hartigan-O'Connor, Manel Esteller, Michael Meulbroek, Maria Luz Calle, Alex Sanchez-Pla, Jose Molto, Beatriz Mothe, Christian Brander, Marta Ruiz-Riol
Summary: This study identifies host DNA methylation profiles and epigenetic cascades that are predictive of subsequent virus control in a kick-and-kill HIV cure strategy.
Article
Immunology
Mina C. Hosseinipour, Craig Innes, Sarita Naidoo, Philipp Mann, Julia Hutter, Gita Ramjee, Modulakgotla Sebe, Lucas Maganga, Michael E. Herce, Allan C. DeCamp, Kyle Marshall, One Dintwe, Erica Andersen-Nissen, Georgia D. Tomaras, Nonhlanhla Mkhize, Lynn Morris, Ryan Jensen, Maurine D. Miner, Giuseppe Pantaleo, Song Ding, Olivier Van der Meeren, Susan W. Barnett, M. Juliana McElrath, Lawrence Corey, James G. Kublin
Summary: The study compared different HIV vaccine administration regimens, with the DNA and protein coadministration regimen showing better results in increasing HIV-1 V1/V2 antibody response rate, and DNA administration by Biojector leading to higher CD4(+) T-cell response rates to HIV envelope protein. Both regimens were found to be safe and promising for advancement into efficacy trials.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Virology
Elena Bruzzesi, Arianna Gabrieli, Davide Bernasconi, Giulia Marchetti, Andrea Calcagno, Diego Ripamonti, Andrea Antinori, Nicola Squillace, Antonella Cingolani, Antonio Muscatello, Alessandra Bandera, Andrea Gori, Stefano Rusconi, Silvia Nozza, INACTION Study Grp
Summary: The introduction of antiretroviral therapy (ART) during primary HIV-1 infection (PHI) can restrict the establishment of HIV reservoirs. This study aimed to assess the effect of three different ART regimens on HIV-DNA load in individuals living with HIV (PLWH) who started ART in PHI. The results showed that regardless of the treatment regimen, the HIV-DNA load in PLWH decreased during the treatment period.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Medicine, General & Internal
Gavin Churchyard, Vicky Cardenas, Violet Chihota, Kathy Mngadi, Modulakgotla Sebe, William Brumskine, Neil Martinson, Getnet Yimer, Shu-Hua Wang, Alberto L. Garcia-Basteiro, Dinis Nguenha, LeeAnne Masilela, Zainab Waggie, Susan van den Hof, Salome Charalambous, Frank Cobelens, Richard E. Chaisson, Alison D. Grant, Katherine L. Fielding
Summary: Completion rates were higher with 3 months of rifapentine-isoniazid compared to 6 months of isoniazid, and a second round of preventive therapy did not provide additional benefit to persons receiving antiretroviral therapy in settings with high tuberculosis transmission.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Pediatrics
Talia Sainz, Inmaculada Casas, Monica Gonzalez-Esguevillas, Luis Escosa-Garcia, Maria Angeles Munoz-Fernandez, Luis Prieto, Maria Jose Gosalbes, Nuria Jimenez-Hernandez, Jose Tomas Ramos, Maria Luisa Navarro, Maria Jose Mellado, Sergio Serrano-Villar, Cristina Calvo
Summary: In this exploratory study, a 4-week course of symbiotics did not increase influenza vaccine immunogenicity in HIV-infected children. Larger studies are warranted to address the potential of modulating the microbiome in children living with HIV.
FRONTIERS IN PEDIATRICS
(2022)
Article
Nanoscience & Nanotechnology
Shuang Li, Bo Wang, Shun Jiang, Yi Pan, Yuhua Shi, Wei Kong, Yaming Shan
Summary: HIV-1 infection remains a global health crisis without a licensed vaccine, but DNA vaccines show promise in combating the virus. This study explores the feasibility of CpG-functionalized SCPs for efficiently delivering DNA vaccines expressing a native-like HIV-1 trimer, which may lead to the development of promising vaccine candidates against HIV-1. The results demonstrate that SCP-based DNA immunization can significantly induce broad humoral and potent cellular immune responses compared to naked DNA vaccination in vivo.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Immunology
Yan Liang, Xiaoping Li, Yourong Yang, Li Xiao, Yumei Liang, Jie Mi, Yong Xue, Wenping Gong, Lan Wang, Jie Wang, Junxian Zhang, Yingchang Shi, Bizhen Peng, Xiaoyang Chen, Weiguo Zhao, Xueqiong Wu
Summary: This study compared the effects of MTB ag85ab and 7 latent DNA vaccines on clearing and preventing activation of latent MTB in a mouse model of latent tuberculosis infection (LTBI). The results showed that all vaccine groups significantly reduced the bacterial count and lesion degree in the lungs of mice, and induced antigen-specific cellular immune responses. Among them, MTB ag85ab and rv2659c, rv1733c DNA vaccines showed the most significant preventive effect.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Cole J. Batty, Mark T. Heise, Eric M. Bachelder, Kristy M. Ainslie
Summary: The COVID-19 pandemic has sparked unprecedented efforts to develop effective and safe vaccines, with hundreds of vaccine candidates proposed and evaluated preclinically. At least 31 candidate vaccines are now in clinical trials, utilizing diverse platforms that have not been approved for human use before.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Immunology
Yunda Huang, Kelly E. Seaton, Martin Casapia, Laura Polakowski, Stephen C. De Rosa, Kristen Cohen, Chenchen Yu, Marnie Elizaga, Carmen Paez, Maurine D. Miner, Colleen F. Kelley, Janine Maenza, Michael Keefer, Javier R. Lama, Magdalena Sobieszczyk, Susan Buchbinder, Lindsey R. Badenj, Carter Lee, Vineeta Gulati, Faruk Sinangil, David Montefiori, M. Juliana McElrath, Georgia D. Tomaras, Harriet L. Robinsonm, Paul Goepfert
Summary: The HVTN 114 study investigated the impact of late boosting with AIDSVAX B/E on the durability and breadth of vaccine-induced immune responses in participants previously enrolled in HVTN 205. The results showed that late boosting with AIDSVAX, alone or in combination with MVA, led to increased binding antibody responses and T-cell responses even years after the initial vaccination.
Article
Food Science & Technology
Woo-Hyun Kim, Hyun-Jeong Lee, Da-Yeon Lee, Chan-Yang Lee, Jeong-Ho Oh, Jeong-Eun Kim, Kiet Vu Tan, Seoung-Ki Kang, Byungkwon Kim, Seong-Bong Hong, Namkyu Yoon, Han -Joo Lee, Soon-Mi Shim
Summary: This study found that standardized krill oil can alleviate alcohol hangover symptoms, lower alcohol and acetaldehyde levels compared to placebo, increase alcohol dehydrogenase and aldehyde dehydrogenase activity, and lower malondialdehyde levels. The antioxidant activity of krill oil is higher than the positive control.
JOURNAL OF FUNCTIONAL FOODS
(2022)
Review
Immunology
Catherine Slack, Paul Ndebele, Mary Allen, Jessica Salzwedel
Summary: The release of the UNAIDS 2021 ethical considerations for HIV prevention trials marks a significant change in the ethics framework for preventive HIV vaccine trials worldwide. This new guidance highlights shifts from the earlier 2012 UNAIDS guidance, impacting both Research Ethics Committees and HIV vaccine researchers.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
(2021)
Article
Immunology
Thomas R. Kosten, Coreen B. Domingo, Colin N. Haile, David A. Nielsen
Summary: Anti-drug vaccines previously failed clinical trials due to inadequate antibody titers and duration. However, new adjuvants can enhance antibody titers and efficacy duration. This study found that the TLR5 adjuvant Entolimod significantly increased antibody titers against diphtheria and tetanus in individuals receiving commercial tetanus-diphtheria (Td) vaccine. Further clinical testing of TLR5 adjuvants like Ent is warranted for anti-drug vaccines.